Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;30(4):410-412.
doi: 10.1080/08998280.2017.11930208.

Evaluation of medication compliance for secondary prevention of acute coronary syndrome

Affiliations

Evaluation of medication compliance for secondary prevention of acute coronary syndrome

Dalvir Gill et al. Proc (Bayl Univ Med Cent). 2017 Oct.

Abstract

To prevent recurrence of acute coronary syndrome (ACS), national practice guidelines recommend use of five-drug combination therapy. Our study assessed the proportion of patients discharged on all five medications following ACS and determined reasons for nonadherence. A retrospective, single-center chart review was conducted at a tertiary academic medical center. Patients 18 years and older who were admitted to the cardiac care unit with a diagnosis of ACS between January 2013 and January 2015 were included. Overall, 200 patients were screened and 155 were included in the study. Half of the patients received all guideline-recommended classes of pharmacological agents at discharge. The other half-78 patients-did not receive the five-drug combination, of whom 48 (62%) had reasons documented for nonadherence. Our study's findings suggest that rates of adherence need to improve given the clear benefits of these medications.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Patient distribution.

Similar articles

Cited by

References

    1. Gislason GH, Rasmussen JN, Abildstr⊘m SZ, Gadsb⊘ll N, Buch P, Friberg J, Rasmussen S, K⊘ber L, Stender S, Madsen M, Torp-Pedersen C. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153–1158. - PubMed
    1. Yetgin T, van der Linden MM, de Vries AG, Smits P, van Mechelen R, Yap S, Boersma E, Zijlstra F, van Geuns R CCR Study Investigators. Current discharge management of acute coronary syndromes: data from the Rijnmond Collective Cardiology Research (CCR) study. Neth Heart J. 2014;22(1):20–27. - PMC - PubMed
    1. Danchin N, Cambou JP, Hanania G, Kadri Z, Genès N, Lablanche J, Blanchard D, Vaur L, Clerson P, Guéret P USIC 2000 Investigators. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J. 2005;150(6):1147–1153. - PubMed
    1. Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Rosenberg Y, O'Rourke R, Shah P, Smith S, Jr PACE-MI Investigators. Beta-blocker use following myocardial infarction: low prevalence of evidence-based dosing. Am Heart J. 2010;160(3):435–442. - PMC - PubMed
    1. Shah BR, Drozda J, Peterson ED. Leveraging observational registries to inform comparative effectiveness research. Am Heart J. 2010;160(1):8–15. - PubMed

LinkOut - more resources